Evidence mapPaperPMID 41664100Full record

ReviewChinese medicine2026

Bridging tradition and modernity: mitochondrial dynamics as a Traditional Chinese Medicine therapeutic target in cardiovascular disease.

Chengyu Du, You Yu, Meng Li, Jin Zhou, You Wang, Xuefeng Guo, Huan Zhang, Zheng Li, Yelei Han, Min Pang and 1 more

Abstract readReview
In one paragraph

Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chengyu Du *Liaoning University of Chinese Medicine, Shenyang, 110032, China.
You Yu *Liaoning University of Traditional Chinese Medicine Affiliated Second Hospital, Shenyang, 110034, China.
Meng LiLiaoning University of Chinese Medicine, Shenyang, 110032, China.
Jin ZhouLiaoning University of Chinese Medicine, Shenyang, 110032, China.
You WangLiaoning University of Chinese Medicine, Shenyang, 110032, China.
Xuefeng GuoLiaoning University of Chinese Medicine, Shenyang, 110032, China.
Huan ZhangLiaoning University of Chinese Medicine, Shenyang, 110032, China.
Zheng LiLiaoning University of Chinese Medicine, Shenyang, 110032, China.
Yelei HanLiaoning University of Chinese Medicine, Shenyang, 110032, China.
Min PangLiaoning University of Traditional Chinese Medicine Affiliated Second Hospital, Shenyang, 110034, China. ywkpangmin@163.com.
Rui YuLiaoning University of Chinese Medicine, Shenyang, 110032, China. ruiyu19690923@163.com.

Funding

The Liaoning Province Science and Technology Program 2023JH2/101600030The National Natural Science Gene Top Project No. 82274494
6 · The paper itself

Abstract

backgroundA pathological link exists between mitochondrial fission/fusion imbalance and cardiovascular disease (CVD). Traditional Chinese Medicine (TCM), based on concepts such as "Qi stagnation and blood stasis" and "Yin-Yang imbalance," helps balance mitochondrial function through the combined effects of multiple components, providing a comprehensive treatment approach for CVD. AIMS OF THE STUDY: To methodically clarify the molecular processes by which TCM formulations, extracts, and bioactive compounds target mitochondrial dynamics to intervene in CVD over the past five years, highlighting their ethnopharmacological significance in "multi-component and multi-target" synergistic actions.

methodsThis study searched PubMed, Web of Science, Wanfang, and VIP databases (2019-2024), using the Boolean search formula: ("cardiovascular disease" OR "CVD") AND ("mitochondrial dynamics" OR "mitochondrial fission" OR "mitochondrial fusion") AND ("Traditional Chinese Medicine" OR "TCM") AND ("active compounds" OR "bioactive components"). After deduplication with EndNote, 183 articles were systematically screened and included, comprising in vitro experiments using cardiomyocyte models, in vivo studies based on animal models of CVD, and mechanistic investigations utilizing ex vivo tissues or cellular experiments (all human clinical trials were excluded).

resultsFormulations such as Buyang Huanwu Decoction (BYHWD) and Qishen Yiqi Dropping Pills (QSYQ) improved heart conditions by reducing dynamin-related protein 1 (Drp1) overactivity and increasing mitofusin 2 (Mfn2) and optic atrophy 1 (OPA1) levels. Bioactive compounds, such as salidroside(Sal), prevented Drp1 from causing mitochondria to split apart by activating the AMP-activated protein kinase(AMPK)/Sirtuin 1(SIRT1) pathway, while astragaloside IV facilitated better mitochondrial fusion to enhance energy utilization.

conclusionTCM manages mitochondria dynamics through multi-target mechanisms, connecting "overall treatment" with "specific targeting" for heart disease therapy. Further ethnopharmacological translation requires standardized screening of bioactive components and the development of innovative drug delivery systems. The study suggests a "Traditional Chinese Medicine-Mitochondrial Dynamics Intervention Model (TCM-MDIM)," which combines organelle-level mitochondrial regulation with the principle of balancing blood and qi to offer novel approaches to the targeted therapy of cardiovascular disorders.

Indexed as

Cardiovascular diseaseMitochondrial dynamicsMulti-target therapyTCM and mitochondrial dynamicsTraditional Chinese medicine

Identifiers

PMID41664100
PMCPMC12888643

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.